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Introduction: The aim of this study was to investigate the influence of symptom duration on treatment response
and on the correlation between improvements in patient reported outcomes (PRO) and objective inflammation in
patients with axial spondylarthritis (SpA) treated with etanercept (ETA) or adalimumab (ADA).
Methods: Data from 112 patients with axial SpA originally enrolled in two randomized controlled clinical trials were
pooled and analyzed after one year of treatment with ETA (n = 66) or ADA (n = 46). Patients with <4 years and ≥4
years of disease were compared for improvement in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath
Ankylosing Spondylitis Functional Index (BASFI), Ankylosing Spondylitis Disease Activity Score (ASDAS), C-reactive
protein (CRP) and magnetic resonance imaging (MRI) score for sacroiliac joints (SIJ).
Results: Patients with <4 years of disease showed a significantly better improvement than longer diseased patients in
BASDAI (3.2 (95% confidence interval (CI): 2.7 to 3.7) vs. 1.7 (1.1 to 2.2)), BASFI, BASMI and ASDAS (1.6 (1.4 to 1.8) vs. 0.9
(0.7 to 1.1)). The change in BASDAI showed a significant correlation with the change in SIJ score (Spearman’s rank
correlation coefficient (rho) = 0.37, P = 0.01) and the change in CRP (rho = 0.45, P = 0.001) in patients with <4 years of
disease. For long diseased patients this correlation was poor and did not achieve statistical significance (rho = 0.13,
P = 0.46; rho = 0.22, P = 0.13 respectively).
Conclusion: The low correlation between change of PROs and change of objective signs of inflammation seen
in axial SpA patients with longer symptom duration treated with tumor necrosis factor-blocker seems to indicate
that inflammation is not the only cause of the patients’ symptoms, while inflammation seems to be the major
cause in short diseased patients.
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Recently new classification criteria have been developed
for axial spondyloarthritis (axSpA) [1] which cover both
patients with ankylosing spondylitis (AS), with typical
radiographic changes of the sacroiliac joints (SIJ) accord-
ing to the modified New York criteria [2], and patients
without the presence of radiographic sacroiliitis, thus, be-
fore the development of chronic structural changes. This
latter group has been labeled as non-radiographic axial
SpA (nr-axSpA) [3]. These criteria allow earlier classifica-
tion, diagnosis and treatment of these patients, and reduc-
tion in the reported unacceptably long delay of between 5
and 10 years between onset of symptoms and making a
diagnosis [4].
In patients with established AS who failed to respond
to conventional treatment with non-steroidal anti-
inflammatory drugs (NSAIDs) TNF-blockers have been
proven to be highly effective. Similar or even higher re-
sponse rates were recently found in patients with nr-
axSpA [5,6]. Younger age, shorter symptom duration or
elevated C-reactive protein (CRP) values were found to
be predictive of a Bath ankylosing spondylitis disease
activity index (BASDAI)-50 response or an assessment
of the SpondyloArthritis International Society (ASAS)-
40 [5,7-9] response to TNF-blockers [5,10].
Currently, it is not clear why patients earlier in the
course of their disease respond better to TNF-blockade
in comparison to longer diseased patients, especially in
the subgroup of nr-axSpA patients who have, by defin-
ition, not yet developed relevant structural damage in
the axial skeleton.
Measurement of disease activity in axSpA currently re-
lies predominantly on patient-reported outcome (PRO)
measures such as the BASDAI and the ASAS-20, ASAS-
40 and partial remission criteria [3]. Only recently was a
new ankylosing spondylitis disease activity score (ASDAS)
developed, which incorporates the CRP value in addition
to PRO measures, or - alternatively - the erythrocyte sedi-
mentation rate [11]. Until now the influence of symptom
duration on PROs, such as the BASDAI and the Bath an-
kylosing spondylitits functional index (BASFI), inflam-
mation parameters, such as CRP and magnetic resonance
imaging (MRI) score, or changes in these measurements,
has not been well investigated. A recent analysis of
TNF-blocker trials in AS patients suggests that there is
only weak correlation between improvement of object-
ive parameters of inflammation, such as CRP or active
inflammation on MRI, and improvement in clinical pa-
rameters [12].
In the present study we pooled data from two TNF-
blocker trials to investigate such a possible dissociation
between PROs and objective parameters of inflammation
in more detail. In the first one, nr-axSpA patients with
no limitation for symptom duration were treated withadalimumab (ADA) and in the second one axSpA pa-
tients, including both AS and nr-axSpA, with a symptom
duration of less than 5 years were treated with etaner-
cept (ETA). This gave us the opportunity to investigate
the time dependency of treatment response and the as-
sociation or dissociation between PROs and objective
signs of inflammation in more detail.
Methods
Patients
Patients of both randomized controlled clinical trials
had an active axSpA defined as BASDAI ≥4 and a back
pain score ≥4, despite concurrent treatment or intoler-
ance to NSAIDs. Treatment periods of one year in pa-
tients receiving ETA or ADA were considered. Patients
with at least two visits under treatment were included in
the analysis. Signed informed consent was obtained from
each patient before any study-related procedures were
performed.
In the etanercept trial [13] 76 patients with active
axSpA (BASDAI ≥4, active inflammatory lesions on MRI
in the SIJs (sacroiliac joints) or the spine) and a symp-
tom duration of less than 5 years were randomized to
receive ETA (n = 40) or sulfasalazine (SSZ) treatment
(n = 36) for one year. SSZ patients who completed week
48 in a status of active disease (n = 26) switched to treat-
ment with ETA. For further details see Song et al. [13].
To investigate the influence of symptom duration on the
outcome, only treatment episodes under ETA were con-
sidered. We included data from 40 patients who received
ETA during the first year (48 weeks) and outcome data
for 26 patients from the SSZ group who received ETA
during the second year (week 48 was used as baseline
visit and the visits at weeks 50 to 108 as the outcome
assessment).
In another trial, 46 patients with early axSpA without
radiological sacroiliitis were randomized to receive ADA
(n = 22) or placebo (n = 24). ADA was given for one year
until week 44. Patients who were randomly assigned to
placebo received it for the first 12 weeks and then
switched to ADA for one further year [5]. For this ana-
lysis we included data from 22 patients who received
ADA during the first year and data for 24 patients who
were treated with ADA from week 12 until week 52
(week 12 was taken as the baseline visit). Retrospectively,
patients from both trials fulfilled the new ASAS classifi-
cation criteria for axSpA [1].
Patients from both studies were pooled for further
analysis and stratified according to their symptom dur-
ation into two (<4 years and ≥4 years) or four groups
(<2 years, 2 to 4 years, 4 to 8 years and ≥8 years). Out of
all patients, 34 patients fulfilled the New York criteria for
AS, of those patients with symptom duration <4 years, and
18 and 16 of those patients with symptom duration ≥4 years.
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CRP status at baseline: CRP value ≤5 mg/l (CRP-
negative) and with a baseline CRP value >5 mg/l
(CRP-positive).
The different groups were analyzed for PROs such as
BASDAI and BASFI, for objective inflammation parame-
ters, such as CRP and MRI SIJ score, and for parameters
that combine subjective patient assessments and object-
ive clinical assessments, such as the Bath ankylosing
spondylitis metrology index (BASMI) and ASDAS. In
both studies, MRI of the SIJ was performed and inflam-
mation was scored by the Berlin MRI score, as described
previously. Differences between baseline and week 48
were analyzed for all parameters.
The 1-year etanercept trial was approved by Landesamt
für Gesundheit und Soziales, Geschäftsstelle der Ethik-
Kommission des Landes, Berlin, Germany. The ethics
approval for the 1-year adalimumab trial was granted
by Ethik-Kommission der Charité - Universitätsmedizin,
Berlin, Germany.
Statistics
Mixed linear models were used to compare the outcome
in PROs, and objective and combined measures after
one year of treatment with ETA or ADA between groups
of different symptom duration. An adjustment for pos-
sible differences at baseline was made, including gender,
human leukocyte antigen (HLA)-B27 status, and CRP
status at baseline as co-variables in these models. By
their nature these mixed models adjust for confounding
by a dropout process. To apply the same type of model
for example, for the outcome in BASDAI as well as the
outcome in non-normally heavily-skewed distributed
CRP values, the CRP values were log transformed. The
mixed model was then applied to these log-transformed
data. For better understanding, adjusted mean scores (so
called least square LS means) with 95% confidence inter-
vals are shown and, for CRP, the corresponding CRP
values transformed back from the log CRP are reported
in the tables.
For the analysis of the association between the change
in scores for the different parameters during TNF-
blockade, partial non-parametric Spearman coefficients
for correlation between changes in PROs and changes
in inflammation scores were calculated. By this method
the dependency of the baseline status is calculated by
linear regression, and the change not explained by the
baseline status is calculated as the correlation between
two parameters. The variation of change in BASDAI (or
BASFI) and MRI (or CRP), adjusted for differences in
the BASDAI and MRI status at baseline, is presented
in the figures. For correlation of baseline values, the
Spearman correlation coefficient was calculated. The non-
parametric Mann-Whitney test, Chi-square test andt-test was used to compare groups according to symp-




The mean symptom duration for the patients pooled
from both studies was 4.7 years, with a similar number
of patients in the <4-years group (58 patients) and
the ≥4-years group (54 patients). Patients’ baseline
characteristics differed in age, BASDAI, BASFI and
CRP but were similar for the other parameters in the
two groups (Table 1). Baseline data are also shown sep-
arately in Table 1 for the ETA and the ADA trial.
Improvement in patients with short versus longer
duration of symptoms
Patients with a symptom duration <4 years improved to
a significantly higher extent in the BASDAI (P = 0.001),
BASFI (P = 0.0003), BASMI (P = 0.01) and ASDAS (P =
0.001) than patients with longer-duration disease after
adjustment for differences in the baseline status (Table 2).
Such differences were not observed for inflammatory pa-
rameters, such as CRP (P = 0.09) and MRI SIJ assess-
ment (P = 0.28). These results were confirmed when the
ETA and the ADA trials were analyzed separately, with
the exception of MRI SIJ assessment, which improved to
a significantly higher extent in patients with short- than
in long-duration disease in the ADA trial (Table 2). In a
sensitivity analysis a further sub-classification of the two
groups was made into patients with less than 2 years or
2 to 4 years of symptoms on the one hand, and into pa-
tients with 4 to 8 years or ≥8 years of symptom duration
on the other hand (Figure 1). This analysis suggested
that the cutoff of 4 years differentiates best between pa-
tients with a very clear and a less clear improvement
in PROs.
Improvement in CRP-positive and CRP-negative patients
Quite interestingly, the differences between patients with
short and longer symptom duration became less evident
in CRP-positive patients. The differences in BASDAI (P =
0.11), BASFI (P = 0.23), BASMI (P = 0.3) and ASDAS (P =
0.07) were no longer significant. In contrast to CRP nega-
tive patients who showed a significantly better response
for PRO parameters (BASDAI, P = 0.001; BASFI, P =
0.001; BASMI, P = 0.01, and ASDAS, P = 0.001) in the case
of short symptom duration (Table 3).
Correlation between improvement in patient-reported
outcomes and improvement in objective measures
At the start of treatment the PROs and measures of in-
flammation (CRP and MRI) were not correlated. Never-
theless, to investigate whether there was at least
Table 1 Baseline characteristics of patients by study and symptom duration group
Pooled data Etanercept Adalimumab
<4 years ≥4 years P-value <4 years ≥4 years P-value <4 years ≥4 years P-value
n = 58 n = 54 n = 42 n = 24 n = 16 n = 30
Symptom duration mean (SD) 2 (1.1) 7.7 (5) 2 (1.1) 5.2 (0.9) 1.9 (1) 9.7 (5.9)
Age, years, mean (SD) 31.7 (8.1) 37.8 (8.4) 0.001 31.6 (8.2) 37 (7.7) 0.01 31.8 (8.1) 38.5 (9.1) 0.02
Male, n (%) 30 (51.7) 28 (51.9) 0.99 25 (59.5) 12 (50) 0.45 5 (31.3) 16 (53.3) 0.15
HLA-B27-positive, n (%) 45 (77.6) 41 (75.9) 0.84 33 (78.6) 22 (91.7) 0.17 12 (75) 19 (63.3) 0.42
Joints with arthritis, mean (SD) 1.1 (3.3) 1.7 (6.4) 0.30 1.4 (3.9) 1.9 (6) 0.33 0.4 (0.7) 1.6 (6.7) 0.86
Joints with enthesitis, mean (SD) 2.5 (3.6) 3.5 (3.8) 0.095 2.7 (4) 3.7 (4.6) 0.41 2 (2.7) 3.3 (3.1) 0.16
BASDAI, mean (SD) 4.9 (1.9) 6 (1.8) 0.004 5 (1.7) 5.5 (2) 0.29 4.7 (2.4) 6.3 (1.5) 0.009
BASFI, mean (SD) 3.8 (2.4) 5 (2.1) 0.007 3.9 (2.2) 4.4 (2.3) 0.34 3.6 (2.8) 5.4 (1.9) 0.01
BASMI mean (SD) 1.5 (1.3) 2.1 (1.8) 0.057 1.7 (1.4) 2.6 (2) 0.04 1.1 (0.9) 1.7 (1.6) 0.16
ASDAS, mean (SD) 3.1 (0.9) 3.1 (0.8) 0.95 3.2 (0.8) 3 (1) 0.49 2.9 (0.9) 3.2 (0.6) 0.22
CRP, mg/l, mean (SD) 9 (9.3) 6.9 (9.6) 0.018 9.7 (10.4) 8.8 (13.4) 0.18 7.4 (6) 5.4 (5.2) 0.14
log CRP, mg/l, mean (SD) 2 (0.7) 1.7 (0.8) 0.018 2.1 (0.8) 1.8 (0.8) 0.26 1.9 (0.7) 1.5 (0.8) 0.16
CRP-negative, n (%) 26 (46.4) 37 (71.2) 0.009 18 (42.9) 16 (66.7) 0.04 8 (50) 21 (70) 0.18
MRI SIJ score, mean (SD) 6.2 (6.1) 4.1 (4.7) 0.08 6.4 (6) 5 (5.7) 0.21 5.4 (7) 3.2 (3.4) 0.61
P-value <0.05 was taken to indicate statistically significant differences between two groups. HLA-B27, human leukocyte antigen-B27; BASDAI, Bath ankylosing
spondylitis disease activity index; BASFI, Bath ankylosing spondylitis functional index; BASMI, Bath ankylosing spondylitis metrology index; ASDAS, ankylosing
spondylitis disease activity score; CRP, C-reactive protein; MRI, magnetic resonance imaging; SIJ, sacroiliac joint.
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provement in inflammations scores (MRI and CRP levels
in CRP-positive patients), the baseline values of these
parameters had to be taken into account. This analysis
resulted in significant correlation only in patients with
short symptom-duration. In this subgroup an improve-
ment in the BASDAI correlated significantly with an im-
provement in the SIJ score (rho = 0.37, P = 0.01) and
with a decrease in CRP values (rho = 0.52, P = 0.005, an-
alyzed for CRP-positive patients only) (Table 4). In con-
trast, these correlations were poor and not significant
(rho = 0.12, P = 0.46, for change in the BASDAI versus
change in MRI-SIJ score; rho = 0.22, P = 0.42, for changeTable 2 Improvement from baseline after one year treatment
Pooled data Eta
Adjusted mean changes (95% CI) P-value Adjusted mean ch
<4 years ≥4 years <4 years ≥4
BASDAI 3.2 (2.7, 3.7) 1.7 (1.1, 2.2) 0.001 3.1 (2.6, 3.6) 1.8
BASFI 2.4 (2, 2.9) 1.2 (0.7, 1.6) 0.001 2.4 (1.9, 2.8) 1.2
BASMI 0.3 (0, 0.6) −0.1 (−0.4, 0.2) 0.09 0.4 (0.1, 0.7) −0.
ASDAS 1.6 (1.4, 1.8) 0.9 (0.7, 1.1) 0.001 1.5 (1.3, 1.8) 1.1
CRP* 1.6 (1.5, 2) 1.6 (1.4, 1.8) 0.72 1.5 (1.4, 1.8) 1.6
MRI SIJ 3.5 (2.9, 4.1) 3 (2.3, 3.6) 0.28 3.9 (3.3, 4.6) 3.7
*Log-transformed CRP results were back transformed; p-value <0.05 was taken to in
changes from baseline under treatment with etanercept or adalimumab (95% CI). O
Bath ankylosing spondylitis disease activity index; BASFI, Bath ankylosing spondyliti
ankylosing spondylitis disease activity score; CRP, C-reactive protein in mg/l; MRI, min BASDAI versus change in CRP) (Table 4 and Figure 2)
for patients with long disease-duration.
The differences in correlation between the adjusted
change scores can also be clearly seen in Figure 2A and B.
In both groups there was a clear variation in the improve-
ment, which could not yet be explained by the baseline sta-
tus of high or lower active disease. In patients with short
symptom-duration, improvement in BASDAI and improve-
ment in MRI went parallel, whereas in longer disease-
duration virtually no correlation was found between the
improvement scores (Figure 2A). Similar results were found
in the subgroup of CRP-positive patients (Figure 2B). Al-
though the overall direction of the association (regressionwith etanercept or adalimumab
nercept Adalimumab
anges (95% CI) P-value Adjusted mean changes (95% CI) P-value
years <4 years ≥4 years
(1.1, 2.6) 0.008 3.2 (2.2, 4.3) 1.6 (0.9, 2.3) 0.02
(0.5, 1.8) 0.006 2.5 (1.5, 3.5) 1.3 (0.5, 2) 0.06
02 (−0.5, 0.4) 0.16 0.02 (−0.6, 0.6) −0.1 (−0.5, 0.3) 0.74
(0.8, 1.4) 0.04 1.7 (1.2, 2.1) 0.8 (0.5, 1.1) 0.003
(1.4, 2.0) 0.60 2.2 (1.6, 3.0) 1.5 (1.2, 1.8) 0.06
(2.8, 4.6) 0.71 7.0 (3.8, 10.1) 2.7 (0.7, 4.7) 0.04
dicate statistically significant differences between two groups; adjusted mean
utcome differences were adjusted for baseline status (see Methods). BASDAI,
s functional index; BASMI, Bath ankylosing spondylitis metrology index; ASDAS,
agnetic resonance imaging; SIJ sacroiliac joint.
Figure 1 Adjusted mean changes from baseline. Adjusted mean changes from baseline are shown for two (<4 and ≥4 years) and four groups
of symptom duration (<4, 2 to 4, 4 to 8 and ≥8 years). BASDAI, Bath ankylosing spondylitis disease activity index; BASFI, Bath ankylosing
spondylitis functional index; ASDAS, ankylosing spondylitis disease activity score; CRP, C-reactive protein and SIJ, sacroiliac joint.
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changes in patients with short disease-duration were closer
to the regression line, whereas the red dots showing pa-
tients with longer disease-duration varied, indicating a
stronger dissociation between change in CRP and change
in BASDAI in the second group.
Discussion
We differentiated between improvement in PROs and
improvement in objective parameters. According to the
findings of others we assumed patients with a shorter
duration of symptoms improved more clearly in PROs
than patients with longer symptom duration. However,we did not expect to observe a similar difference in ob-
jective parameters. Therefore, the main objective of this
study was to investigate the associations between the im-
provement in subjective and objective measures within
groups of patients with axSpA with different symptom
duration.
We could confirm earlier data that the response rate to
TNF-blocker therapy measured by PROs is indeed clearly
better if axSpA patients are treated early in the course of
their disease [10,14]. Findings of others described higher
BASDAI-50, ASAS-20 or ASAS-40 response rates in pa-
tients with shorter symptom duration or in patients of
younger age [5,8,10,12,14,15]. We focused on early disease
Table 3 Results for CRP-positive and CRP-negative patients
CRP-positive patients CRP-negative patients
Baseline value Adjusted mean changes (95% CI) P-value Baseline value Adjusted mean changes (95% CI) P-value
<4 years ≥4 years <4 years ≥4 years
n = 30 n = 15 n = 26 n = 37
BASDAI 5.4 3.3 (2.7, 4.0) 2.4 (1.5, 3.3) 0.11 5.5 3 (2.3, 3.7) 1.3 (0.7, 1.9) 0.001
BASFI 4.2 2.4 (1.8, 3.0) 1.8 (0.9, 2.7) 0.23 4.5 2.4 (1.8, 3.1) 0.9 (0.4, 1.5) 0.001
BASMI 1.5 0.1 (−0.3, 0.4) 0.4 (−0.1, 0.9) 0.30 2.0 0.5 (0, 1) −0.3 (−0.6, 0.1) 0.01
ASDAS 3.6 1.9 (1.6, 2.2) 1.5 (1.1, 1.9) 0.07 2.8 1.3 (1, 1.6) 0.6 (0.3, 0.8) 0.001
CRP* 13.8 2.7 (2.2, 3.3) 2.1 (1.5, 3) 0.20 3.6 1.2 (1, 1.5) 1.2 (1, 1.4) 0.86
MRI SIJ 6.6 4.6 (3.6, 5.7) 3.5 (2, 4.9) 0.19 3.8 2.5 (1.8, 3.2) 2.5 (1.9, 3.1) 0.96
*Log-transformed CRP results were back-transformed; P-value <0.05 was taken to indicate statistically significant differences between two groups; adjusted mean
changes from baseline under treatment with etanercept or adalimumab (95% CI). Outcome differences were adjusted for baseline status (see Methods). BASDAI,
Bath ankylosing spondylitis disease activity index; BASFI, Bath ankylosing spondylitis functional index; BASMI, Bath ankylosing spondylitis metrology index; ASDAS,
ankylosing spondylitis disease activity score; CRP, C-reactive protein in mg/l; MRI, magnetic resonance imaging; SIJ, sacroiliac joint.
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symptom duration had significantly better improvement
in PROs (BASDAI, P = 0.001; BASFI, P = 0.001) than pa-
tients with longer symptom duration (Table 2). No signifi-
cant differences were observed between the subgroups
of <2 years and 2 to 4 years of symptom duration. Although
these subgroups were of small size these results suggest a
cutoff of around 4 years can be used to identify a window
of opportunity for early therapy regarding a good treat-
ment response to TNF-blockers. Indeed, symptom dur-
ation of less than 3 years [6,16] or less than 5 years [13]
have been associated with a clinical remission rate of
about 50% in axSpA patients treated with TNF-blockers,
and a cutoff of 5 years of symptoms differentiated good
and bad responders in an nr-axSpA trial with ADA [10].
As expected we found no difference in the improve-
ment of objective parameters of inflammation such as
MRI inflammation (P = 0.28) and CRP (P = 0.72) be-
tween the disease groups. Previous studies suggest thatTable 4 Correlation coefficients
All
Baseline1 BASDAI versus SIJ −0
BASDAI versus CRP3 0.0
BASFI versus SIJ −0
BASFI versus CRP3 −0
SIJ versus CRP3 −0
Differences2 BASDAI versus SIJ 0.2
BASDAI versus CRP3 0.4
BASFI versus SIJ 0.1
BASFI versus CRP3 0.1
SIJ versus CRP3 0.4
1Spearman correlation coefficient. 2Partial Spearman correlation coefficients of diffe
3CRP-positive patients. BASDAI, Bath ankylosing spondylitis disease activity index; B
spondylitis metrology index; ASDAS, ankylosing spondylitis disease activity score; Cthe degree of inflammation measured by CRP or MRI is
predictive for BASDAI or ASAS response [8,14]. For the
first time, we separately analyzed the influence of symp-
tom duration on treatment response for CRP-positive and
CRP-negative patients. Quite interestingly, the difference
in the treatment response in favor of patients with short-
duration disease was less clear in CRP-positive patients
with only a non-significant trend in favor of the latter
group. In contrast, all PRO parameters were significantly,
and most probably with more clinical relevance, better
in patients with short symptom-duration in the CRP-
negative group, indicating that the probability of a good
clinical response is rather low in TNF-blocker-treated pa-
tients with long symptom-duration who are CRP-negative.
Additionally we investigated the associations between
objective and subjective measures at start of treatment
and after one year of treatment with a TNF-blocker.
Similar to others [17,18], we observed only weak, or in
patients with longer symptom-duration, even inverseCorrelation coefficient (P-value)
patients <4 years ≥4 years
.1 (0.3) 0.1 (0.3) −0.3 (0.02)
4 (0.8) 0.1 (0.7) −0.1 (0.8)
.04 (0.7) 0.2 (0.2) −0.3 (0.1)
.2 (0.2) −0.2 (0.4) −0.2 (0.6)
.4 (0.01) −0.5 (0.005) 0 (0.995)
(0.1) 0.4 (0.01) 0.12 (0.5)
(0.02) 0.5 (0.01) 0.22 (0.4)
(0.3) 0.4 (0.01) 0.1 (0.7)
(0.5) 0.3 (0.2) 0.03 (0.9)
(0.02) 0.04 (0.9) 0.8 (0.01)
rences adjusted for the baseline status of the corresponding parameters.
ASFI, Bath ankylosing spondylitis functional index; BASMI, Bath ankylosing
RP, C-reactive protein; SIJ, sacroiliac joint assessment on MRI.
Figure 2 Correlation between change in Bath ankylosing
spondylitis disease activity index (BASDAI) and change in
sacroiliac joints (SIJs) (A), and change in C-reactive protein
(CRP) score (B). (A) Improvement in BASDAI and SIJ score is
presented after one year of treatment adjusted for baseline.
(B) Improvement in BASDAI and log CRP values is presented for
CRP-positive patients after one year of treatment adjusted for baseline.
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and BASFI) and objective measures of inflammation (CRP
and MRI inflammation score). The interesting question is
whether the improvement in BASDAI and BASFI is also
unrelated to the improvement measured in MRI scores or
CRP. To address this question, the fact that a patient with
high CRP or high BASDAI score at baseline had a higher
chance of a significant improvement than patients with
moderate disease activity. Therefore, we adjusted the ob-
served changes for differences in the baseline values.
We show here for the first time that these correlations
were clearly better in axSpA patients with short symptom-
duration. In the patients with short-duration disease,
improvement in PROs such as BASDAI and objective pa-
rameters of inflammation, such as the amount of MRI in-
flammation (Figure 2A) or CRP (Figure 2B) was in thesame positive direction in all patients. These correlations
were only statistically significant in this group of patients.
In patients with longer symptom-duration these correla-
tions were very weak, indicating clear dissociation between
change in PROs and changes in objective parameters.
Worsening of the BASDAI despite improvement of in-
flammatory parameters was found only for some patients
in the long-duration disease group. Machado et al. found
good correlation between change in MRI and CRP but no
correlation between MRI change and change in PROs,
such as the BASDAI [12]. However, they did not take the
influence of the baseline status into account and they
could not differentiate between patients with long- and
short-term disease because the number of patients with
short symptom-duration was only small in this study.
The data presented here indicate that early in the course
of the disease the patient’s symptoms are predominantly
caused by inflammation, whereas later in the course, symp-
toms might additionally be due to various other causes,
among which inflammation is only one. This might also
explain why TNF-blockers, which are highly effective anti-
inflammatory drugs, work less well in these patients. On-
going, often insufficiently treated inflammation of the axial
skeleton over years might result in other causes of pain,
such as secondary fibromyalgia, chronic muscle imbalance,
non-physiological stress or impact on joints and enthuses,
and other less well-defined causes. These data also stress
the importance of early diagnosis and early treatment of
axial SpA patients to achieve the best improvement in pa-
tients’ symptoms. Whether such an early diagnosis and
early treatment also has an effect on the prevention of
structural bony damage has yet to be shown [19].Conclusion
Our data suggest there is already a disconnection be-
tween improvement in subjective and objective signs of
disease activity in patients with axial spondyloarthritis
after four years of symptom duration. We only found
clear correlation between changes in inflammation scores
and changes in patient-reported outcomes in patients with
short disease-duration. These results add a new perspec-
tive to earlier findings on low association between signs
and symptoms and CRP positivity/MRI inflammation in
axSpA patients.
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